Assessment of Fracture Risk

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on Assessment of Fracture Risk

Osteoporosis-related fractures are associated with significant morbidity, mortality, and health care expenditure worldwide. The low sensitivity of bone density testing alone to predict fractures has led to the development of…

read more

Teriparitide Update

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on Teriparitide Update

Teriparitide (TPD) is a novel anabolic agent that stimulates bone formation. TPD reduces risk of vertebral and nonvertebral fracture. Due to its positive effects on bone formation, many new uses…

read more

The RANKL Pathway and Denosumab

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on The RANKL Pathway and Denosumab

Denosumab (Prolia) is a fully human monoclonal antibody directed against receptor activator of nuclear factor-κB ligand (RANKL), which interferes with the formation, activation, and survival of osteoclasts. It was approved…

read more

Osteoporosis in Men: Update 2011

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on Osteoporosis in Men: Update 2011

During the past year several review articles have been published on the topic of osteoporosis in men. These reviews have highlighted recommendations for measuring bone mineral density (BMD) in older…

read more

Update on Glucocorticoid-Induced Osteoporosis

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on Update on Glucocorticoid-Induced Osteoporosis

Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and fractures are the most frequent adverse effects of this medication. Glucocorticoids have several direct and indirect adverse effects…

read more

Calcium and Vitamin D Controversies

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on Calcium and Vitamin D Controversies

Controversies regarding appropriate use of vitamin D and calcium are predominately related to the extraskeletal effects. Calcium and vitamin D are essential for bone health. The concerns regarding calcium and…

read more

Emerging Therapies for Osteoporosis

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on Emerging Therapies for Osteoporosis

This article reviews the conceptual framework for agents that are antiresorptive or anabolic, including pathways that affect bone formation and resorption, and the steps in those pathways that are targets…

read more

Duration of Treatment in Postmenopausal Osteoporosis: How Long to Treat and What are the Consequences of Cessation of Treatment?

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on Duration of Treatment in Postmenopausal Osteoporosis: How Long to Treat and What are the Consequences of Cessation of Treatment?

Although a variety of medications are effective for the treatment of postmenopausal osteoporosis, there is concern that long-term use may incur side effects. Consequently, some have proposed discontinuing or temporarily…

read more
Get Clinical Tree app for offline access